Jorge E. Rico-Fontalvo

Barranquilla, ATL, Colombia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

The cardiorenometabolic syndrome as a new clinical paradigm in precision medicine

The cardiorenometabolic syndrome as a new clinical paradigm in precision medicine

Journal: Archivos de cardiologia de Mexico

Published: July 01, 2026

Incretin analogues as cardiovascular agents: a state-of-the-art review.

Incretin analogues as cardiovascular agents: a state-of-the-art review.

Journal: Frontiers in endocrinology

Published: June 03, 2026

Efficacy and Safety of Finerenone in Patients Aged 65 Years or Older with Diabetic Kidney Disease: Subgroup Analysis of the FINDKDLATAM Study.

Efficacy and Safety of Finerenone in Patients Aged 65 Years or Older with Diabetic Kidney Disease: Subgroup Analysis of the FINDKDLATAM Study.

Journal: Medicina (Kaunas, Lithuania)

Published: May 08, 2026

Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.

Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: December 12, 2025

Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial.

Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial.

Journal: World journal of nephrology

Published: October 29, 2025

Inflammatory and lipotoxicity mechanisms in obesity related CKD.

Inflammatory and lipotoxicity mechanisms in obesity related CKD.

Journal: Frontiers in nephrology

Published: August 11, 2025

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.

Journal: Frontiers in endocrinology

Published: July 10, 2025

Obesity-Related Kidney Disease: A Growing Threat to Renal Health.

Obesity-Related Kidney Disease: A Growing Threat to Renal Health.

Journal: International journal of molecular sciences

Published: May 23, 2025

Kidney Health Programs in Latin America: Results of the SLANH Survey 2024.

Kidney Health Programs in Latin America: Results of the SLANH Survey 2024.

Journal: Seminars in nephrology

Published: May 03, 2025

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.

Journal: Frontiers in endocrinology

Published: April 03, 2025

Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1.

Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1.

Journal: Global heart

Published: January 29, 2025

S.E.N., SLANH, and SEEDO consensus report on obesity-related kidney disease: proposal for a new classification.

S.E.N., SLANH, and SEEDO consensus report on obesity-related kidney disease: proposal for a new classification.

Journal: Kidney international

Published: January 11, 2025

Showing 1-12 of 33

Last Updated: 09/26/2026